Compare · BAX vs BJDX
BAX vs BJDX
Side-by-side comparison of Baxter International Inc. (BAX) and Bluejay Diagnostics Inc. (BJDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BAX and BJDX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BAX is the larger of the two at $42.70B, about 1403.7x BJDX ($30.4M).
- Over the past year, BAX is down 40.5% and BJDX is down 71.2% - BAX leads by 30.6 points.
- BAX has been more active in the news (5 items in the past 4 weeks vs 3 for BJDX).
- BAX has more recent analyst coverage (25 ratings vs 1 for BJDX).
- Company
- Baxter International Inc.
- Bluejay Diagnostics Inc.
- Price
- $18.15-1.44%
- $1.95-2.50%
- Market cap
- $42.70B
- $30.4M
- 1M return
- +5.95%
- -4.41%
- 1Y return
- -40.53%
- -71.15%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 1
Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Bluejay Diagnostics Inc.
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Latest BAX
- Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
- SEC Form 3 filed by new insider Foster Julie
- SEC Form 3 filed by new insider Wallace Steven P.
- SEC Form 3 filed by new insider Teaff James
- Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
- Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
- Baxter to Host Annual Meeting of Stockholders in Virtual Format
- Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot
- SEC Form DEFA14A filed by Baxter International Inc.
- SEC Form DEF 14A filed by Baxter International Inc.
Latest BJDX
- SEC Form PRE 14A filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
- SEC Form 10-K filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook